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may not be truly independent but rather an 
intrinsic part of the senescence pathway 
described by Krizhanovsky et al. Intrigu-
ingly, NK cells, which are attracted by the 
senescent HSCs, can induce apoptosis of 
many cell types including HSCs (Radaeva 
et al., 2006). It remains to be seen whether 
this new model is specific to liver fibrosis 
or whether it represents a more general 
homeostatic mechanism involved in other 
wound healing responses. Regardless, 
this new study clearly demonstrates that 
the role of cellular senescence extends far 
beyond cancer prevention.
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During nuclear export, Gle1 (the nuclear-pore-associated mRNA export factor) activates the 
DEAD-box protein Dbp5 to remodel exported mRNA-protein complexes on the cytoplasmic face 
of the nuclear pore complex. In this issue, Bolger et al. (2008) now report additional roles for Gle1 
in translation initiation and termination.Mature cytoplasmic messenger RNAs 
(mRNAs) ready for translation are the 
products of a complex maturation path-
way that starts concomitantly with tran-
scription in the nucleus and includes 
nuclear pre-mRNA processing, mRNA 
export through nuclear pore complexes 
(NPCs), and remodeling of mRNA-ribo-
nucleoprotein (mRNP) complexes in the 
cytoplasm. Recently, it has become clear 
that many of the consecutive events in 
this pathway are tightly interconnected, 
and the number of factors that influence 
multiple distinct steps in the mRNP bio-
genesis pathway is steadily increas-
ing. New work by Bolger et al. (2008) in 
this issue now explores a fresh twist on 
the double duty carried out by proteins 
involved in mRNP biogenesis, in this case 
the role of the mRNA export factor Gle1 in 
translation initiation and termination.
Successful export of an mRNA first 
requires the association of the mRNA 
with proteins in the nucleus to form an 564 Cell 134, August 22, 2008 ©2008 Elseviexport-competent mRNP. Recognition of 
this mRNP by the nuclear export receptor 
Mex67 (TAP/NXF1 in vertebrates) is then 
needed to facilitate mRNP translocation 
through NPCs. In addition, several other 
factors are necessary to ensure efficient 
mRNA export. Two such essential pro-
teins are the mRNA export factor Gle1 
and its partner Dbp5 (for review, see 
Cole and Scarcelli, 2006). Dbp5 belongs 
to the family of DEAD-box-containing 
RNA helicases, which use the energy of 
ATP binding and hydrolysis to rearrange 
RNA structures or to dissociate proteins 
from RNA. Under steady-state condi-
tions, a pool of both Dbp5 and Gle1 is 
strategically positioned on the cytoplas-
mic fibrils of the NPC to remodel mRNPs 
as soon as they emerge from the NPC 
channel. Elegant previous studies in the 
budding yeast Saccharomyces cerevi-
siae revealed that the low intrinsic, RNA-
dependent ATPase activity of Dbp5 is 
greatly stimulated by NPC-associated er Inc.Gle1 and its soluble cofactor inositol 
hexakisphosphate (IP6) (Alcazar-Roman 
et al., 2006; Weirich et al., 2006). This 
control of Dbp5 activation by Gle1 (and 
IP6), which is thought to be locally cou-
pled to the NPC, is critical for efficient 
mRNA export. It is also involved in mRNP 
remodeling events such as the disso-
ciation of the RNA-binding protein Nab2 
(Tran et al., 2007) and the export receptor 
Mex67 (Lund and Guthrie, 2005), which 
may contribute to the directionality of the 
mRNA export process.
In addition to the pools of Dbp5 and 
Gle1 attached to the NPC, both proteins 
are also found in the cytoplasm. Recent 
work in budding yeast has revealed a sur-
prising cytoplasmic role for yeast Dbp5 
in the termination of translation (Gross et 
al., 2007). Translation termination occurs 
through recognition of a stop codon in 
the ribosomal A site by the polypep-
tide release factor eRF1, which together 
with eRF3 stimulates polypeptidyl-tRNA 
hydrolysis. In the recent work, 
Dbp5 was shown to be asso-
ciated with polysomes and 
to interact with eRF1/Sup45. 
It was also required for the 
recruitment of the release 
factor eRF3/Sup35 into ter-
mination complexes and for 
efficient read-through of stop 
codons (Gross et al., 2007). 
But how Dbp5 becomes acti-
vated to function in transla-
tion termination has remained 
unclear. Bolger et al. (2008) 
now provide a possible mech-
anism for Dbp5 activation by 
demonstrating that both Gle1 
and its coactivator IP6 are nec-
essary for correct termination 
of translation in budding yeast. 
These investigators showed 
that cells that are impaired in 
Gle1 function (gle1 mutants) 
exhibit sensitivity to transla-
tional inhibitors and synergis-
tic growth defects when com-
bined with mutant polypeptide 
release factors, as previously 
observed with dbp5 mutants. 
Further, gle1 mutants fail to 
efficiently recruit eRF3/Sup35 
to polysomes and promote 
read-through of stop codons. 
Because mutations in com-
ponents of the IP6 pathway 
display similar defects, these 
data point to a role for Gle1 
and IP6 in translation termina-
tion via the activation of Dbp5 
(Figure 1).
Given that the requirements 
for Dbp5 activation in mRNP 
remodeling after export and 
translation termination are 
identical, the question arises 
whether the failure observed 
in translational termination is 
the secondary consequence 
of earlier defects linked to 
pre-mRNA export. Several 
lines of evidence provided by the Bolger 
et al. study argue against this: (1) the gle1 
temperature-sensitive alleles used in this 
study have only a mild mRNA export 
defect at their permissive temperature 
(23°C) but are still sensitive to transla-
tional inhibitors and show read-through 
defects; (2) yeast strains harboring muta-
tions in other factors involved in mRNA 
export, such as the nucleoporins that 
are required for Dbp5 and Gle1 docking 
to the NPC, have severe mRNA export 
defects but behave normally with respect 
to translation termination and are insen-
sitive to translation inhibitors; and (3) the 
stop codon read-through assays used in 
the study were normalized to a 
reporter that is equally sensi-
tive to mRNA export defects. 
Thus, it seems unlikely that 
the observed requirement for 
Dbp5, Gle1, and IP6 in trans-
lational termination is an indi-
rect consequence of defective 
mRNA export. The isolation 
of gle1 mutant alleles that 
are specifically impaired in 
translation termination would 
further facilitate our under-
standing of the role of Gle1 in 
translation termination.
So how can the observed 
defects in translation termina-
tion be explained? Whereas 
loading of eRF1/Sup45 into 
polysomes is normal in yeast 
strains impaired in Dbp5 or 
Gle1 function, the recruit-
ment of eRF3/Sup35 is com-
promised. Moreover, Bolger 
and colleagues show that 
Gle1 can directly interact with 
eRF1/Sup45 and may there-
fore target Dbp5 to the termi-
nation complex. Because the 
activation of Dbp5 is similar in 
both the late steps of mRNA 
export and translation ter-
mination, one can assume 
that Dbp5’s RNP remodeling 
activity triggers an event that 
promotes eRF3/Sup35 asso-
ciation. The molecular nature 
of this event and whether it 
involves RNA unwinding or 
protein removal is still unclear. 
Further, it remains to be seen 
where this RNP remodeling 
step would occur, presum-
ably either directly on the 
mRNP close to the termina-
tion codon or at the ribosome 
close to the A site. Remark-
ably, translation termination 
can be reconstituted in an in 
vitro system using purified 
yeast proteins and short model mRNAs 
(Pisarev et al., 2007). Given that the asso-
ciation of release factors with ribosomes 
is elegantly recapitulated in this in vitro 
assay, it may offer a great experimental 
system for studying the contribution of 
Dbp5, Gle1, and IP6 to the formation of 
termination complexes in the future.
figure 1. Roles for Gle1 and Dbp5 in mRnP Biogenesis and 
Translation
mRNA export: Upon exit of mRNPs from the nuclear pore complex (NPC), the 
NPC-associated mRNA export factor Gle1, together with inositol hexakispho-
sphate (IP6), activates the ATP-dependent RNA helicase Dbp5, resulting in the 
dissociation of the mRNA export factors Nab2 and Mex67. Dbp5 may arrive 
at NPCs along with exported mRNPs because it is a shuttling protein that 
already binds to pre-mRNAs in the nucleus.
Translation initiation: eIF4G serves as a scaffold to assemble factors like the 
eIF3 complex, polyA binding protein (PABP), and eIF4E. Gle1 is required for 
efficient initiation and interacts with components of the eIF3 complex. Gle1’s 
function in initiation is independent of IP6, and the role of Dbp5 remains to 
be clarified.
Translation termination: During termination of translation, Gle1 and Dbp5 
promote the incorporation of eRF3/Sup35 into termination complexes. Gle1 
directly interacts with eRF1/Sup45 and so may couple Dbp5 activation to 
terminating ribosomes. Proper recognition of termination codons requires 
IP6, Gle1, and Dbp5, suggesting that Dbp5’s ATPase activity is crucial for 
this process.Cell 134, August 22, 2008 ©2008 Elsevier Inc. 565
The dissociation of 80S ribosomes 
after termination is promoted by trans-
lation initiation factors eIF1, eIF1A, and 
the eIF3 complex (Pisarev et al., 2007). 
In light of this, the second observation 
by Bolger et al. implicating Gle1 in the 
initiation step of translation is particu-
larly exciting. Bolger and colleagues 
link Gle1 with two subunits of the eIF3 
complex: Gle1 has genetic interactions 
with Nip1 (eIF3c) and physically asso-
ciates with Prt1 (eIF3b). Furthermore, 
cells lacking functional Gle1 accumulate 
80S monosomes, indicative of a defect 
in translation initiation. Although cells 
lacking Dbp5 also exhibit accumulation 
of 80S monosomes (Gross et al., 2007), 
there is no evidence yet for a genetic or 
physical interaction of Dbp5 with the 
translation initiation machinery. More-
over, the IP6 pathway was not found to 
be required for initiation, suggesting that 
Gle1/IP6-dependent activation of Dbp5 
is not the mechanism underlying Gle1’s 
role in initiation. Rather, the authors put 
forward the attractive model that Gle1 
could contribute to ribosomal sub-
unit recycling in conjunction with eIF3, 566 Cell 134, August 22, 2008 ©2008 Elsevie
With the discovery that RNA interfer-
ence (RNAi) occurs in mammalian cells 
(Elbashir et al., 2001), it immediately 
became clear that RNAi is not only a 
powerful tool for basic research but 
also may represent a new therapeu-
tic approach against viral infections 
and cancer. Numerous studies have 
established the proof of concept that 
diseases can be targeted by therapeu-
silencing HIV-1
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RNA interference holds great pr
small interfering RNAs (siRNAs) 
Kumar et al. (2008) now report a t
infection in a humanized mouse thereby helping to couple translation 
termination to the next round of initia-
tion. Alternatively, Gle1 might influence 
initiation independently of its role in 
termination. More biochemical experi-
ments will be required to clarify the role 
of Gle1, and potentially Dbp5, in transla-
tion initiation.
The new roles for Gle1 may have impli-
cations for understanding human dis-
eases caused by mutations in human 
GLE1 (hGLE1). A recent study reported 
that heritable mutations in hGLE1 are the 
cause of lethal congenital contracture 
syndrome type 1 (LCCS1), a fetal motor 
neuron disease associated with prena-
tal death. Two related disorders, LCCS2 
and LCCS3, have also been analyzed, 
and those mutations map to factors act-
ing in the phosphatidyl inositol pathway 
(Nousiainen et al., 2008, and references 
therein). The new findings by Bolger et al. 
implicating Gle1 and IP6 in mRNA export 
and translation beg the question of 
whether these syndromes could be due 
to defects in translation or mRNA export. 
Future functional analysis of the inher-
ited mutations in these diseases could r Inc.
tic RNAi, and several small interfer-
ing RNAs (siRNAs) are currently being 
tested in clinical trials (Grimm and Kay, 
2007). Despite these rapid advances, 
significant hurdles still need to be 
overcome for the widespread thera-
peutic application of siRNAs. Perhaps 
the greatest challenge is the delivery 
of effective quantities of siRNAs into 
the cytoplasm of relevant target cells 
 In Vivo
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.de
omise for antiviral therapy, but d
into the right target cells in vivo
echnique to target siRNAs specifi
model of HIV/AIDS.provide valuable insights into the molec-
ular defects underlying human pathology 
caused by mutations in GLE1.
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Biol. 8, 668–676.in vivo (Dykxhoorn and Lieberman, 
2006). There are additional challenges 
for using siRNAs in the treatment of 
HIV-1 infection, including validating the 
approach in a relevant animal model 
and preventing the emergence of vari-
ants resistant to treatment because of 
the high sequence diversity of the virus. 
In this issue, Kumar et al. (2008) exploit 
a series of recent technical advances to 
elivering effective quantities of 
 represents a major challenge. 
cally to T cells to suppress viral 
